Intellia Therapeutics, Inc.
Stock Details
Is it expensive?
Trailing P/E Ratio
-3.56
Forward P/E Ratio
-4.64
PEG Ratio
0.10
-2.89
Price-to-Sales (TTM)
23.65
2.35
5.77
Market Cap
1.60B
1.24B
Is it profitable?
Net Profit Margin (TTM)
0.00%
Gross Profit Margin
0.00%
Diluted EPS (TTM)
-3.88
-53.48%
67.67M
Is it growing?
78.80%
78.79%
Is it risky?
1.99
13.90
5.08
93.33M
Who owns it?
85.40%
4.61%
37.37%
116.32M
111.94M
Does it pay?
0.00%
0.00%
--
--
How much cash?
449.88M
-394.74M
-233.29M
3.81
- Price
- 13.87
- Percent Change
- +0.32 (2.36%)
- Previous Close
- 13.55
- Open
- 14.47
- Low
- 13.57
- High
- 14.48
52-Week Range Position (52WRP)
Below Average
Below Average
within its 1-year price range
$13.87
From 52W Low
+132.33%
From 52W High
-50.90%
Today
+2.36%
1Y Change
+95.90%
6M
$25.46
3M
$10.38
1M
$13.89
Today
$13.87
From 52W Low
+132.33%
From 52W High
-50.90%
Today
+2.36%
1Y Change
+95.90%
6M
$25.46
3M
$10.38
1M
$13.89
Today
$13.87
Below Average
within its 1-year price range
$13.87
Multi-Timeframe Analysis (MTA)
Divergence
Timeframes disagree. Short and long-term momentum are pulling in different directions, which historically signals higher uncertainty and potential turning points. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
-0.1%
3M
+33.6%
6M
-45.5%
1Y
+95.9%
Rate of Change (ROC)
Decelerating
Price has reversed, now falling vs its usual uptrend. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Intellia Therapeutics, Inc.
- Founded
- Jan 1, 2014
- Founders
- Jennifer Doudna, Luciano Marraffini, Derrick J. Rossi
- CEO
- John M. Leonard
- Employees
- 377
- Fiscal Year End
- Dec 31, 2025
- Address
57 Cambridge Parkway, Suite 200A
Cambridge
Massachusetts
02142
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.intelliatx.com
Indicators
Operating Cash Flow
-394.74M
Net Income
-412.69M
Backed by Cash
0.96
Earnings closely match operating cash flow. This is the healthy baseline: profits are genuine and not artificially inflated.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Indicators
Operating Cash Flow
-394.74M
Net Income
-412.69M
Backed by Cash
0.96
Earnings closely match operating cash flow. This is the healthy baseline: profits are genuine and not artificially inflated.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Stock Details
Is it expensive?
Trailing P/E Ratio
-3.56
Forward P/E Ratio
-4.64
PEG Ratio
0.10
-2.89
Price-to-Sales (TTM)
23.65
2.35
5.77
Market Cap
1.60B
1.24B
Is it profitable?
Net Profit Margin (TTM)
0.00%
Gross Profit Margin
0.00%
Diluted EPS (TTM)
-3.88
-53.48%
67.67M
Is it growing?
78.80%
78.79%
Is it risky?
1.99
13.90
5.08
93.33M
Who owns it?
85.40%
4.61%
37.37%
116.32M
111.94M
Does it pay?
0.00%
0.00%
--
--
How much cash?
449.88M
-394.74M
-233.29M
3.81
- Price
- 13.87
- Percent Change
- +0.32 (2.36%)
- Previous Close
- 13.55
- Open
- 14.47
- Low
- 13.57
- High
- 14.48
52-Week Range Position (52WRP)
Below Average
Below Average
within its 1-year price range
$13.87
From 52W Low
+132.33%
From 52W High
-50.90%
Today
+2.36%
1Y Change
+95.90%
6M
$25.46
3M
$10.38
1M
$13.89
Today
$13.87
From 52W Low
+132.33%
From 52W High
-50.90%
Today
+2.36%
1Y Change
+95.90%
6M
$25.46
3M
$10.38
1M
$13.89
Today
$13.87
Below Average
within its 1-year price range
$13.87
Multi-Timeframe Analysis (MTA)
Divergence
Timeframes disagree. Short and long-term momentum are pulling in different directions, which historically signals higher uncertainty and potential turning points. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
-0.1%
3M
+33.6%
6M
-45.5%
1Y
+95.9%
Rate of Change (ROC)
Decelerating
Price has reversed, now falling vs its usual uptrend. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Intellia Therapeutics, Inc.
- Founded
- Jan 1, 2014
- Founders
- Jennifer Doudna, Luciano Marraffini, Derrick J. Rossi
- CEO
- John M. Leonard
- Employees
- 377
- Fiscal Year End
- Dec 31, 2025
- Address
57 Cambridge Parkway, Suite 200A
Cambridge
Massachusetts
02142
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.intelliatx.com